Entecavir (ETV) demonstrates consistent responses throughout baseline disease and demographic subgroups for the treatment of lamivudine-refractory HBeAg(+) patients with chronic hepatitis B
Author
Goodman, Z.
Hindes, R.
Batur, Y.
Vaughan, J.
Brett-Smith, H.
Yurdaydin, C.
Senturk, H.
Boron-Kaczmarska, A.
Raptopoulou-Gigi, M.
Metadata
Show full item recordCollections
- Bildiri [64839]